S&K Therapeutics

S&K Therapeutics is a South Korean biotechnology company specializing in the discovery and development of innovative immunomodulatory and regenerative medicines. Founded in 2020 by Dr. Sangdun Choi, an Emeritus Professor at Ajou University, the company leverages an AI-driven drug discovery platform and molecular docking simulations to design and optimize novel therapeutic candidates. S&K Therapeutics' pipeline is divided into two primary research areas: Innate Immune Signaling Modulation, which focuses on small-molecule inhibitors targeting the NLRP3 inflammasome, MyD88, and Toll-like receptors (TLRs) for neuroinflammatory and autoimmune diseases; and Regenerative Peptide Therapeutics, which develops receptor-directed mimetic peptides (such as FGFR1 and VEGFR2 activators) to promote tissue repair, angiogenesis, and stem cell recruitment. The company is actively advancing its preclinical assets, including the brain-penetrant NIM5 series for multiple sclerosis and Alzheimer's disease, the TLR7/9 dual inhibitor S&K-101 for systemic lupus erythematosus and psoriasis, and the FGFR1-activating peptide FAP1 for diabetic wound healing.